AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26176018 — intervention group
Group type: EXPERIMENTAL
Intervention: NiTi heat-activated arch wires
Number of subjects: 22
Study 26176018 — intervention group
Group type: COMPARATOR
Intervention: Conventional NiTi arch wires
Number of subjects: 22
Study 23117679 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 78
Study 23117679 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 78
Study 23117679 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic eosinophil increase
Number of subjects: 78
Study 21689115 — intervention group
Group type: EXPERIMENTAL
Intervention: Test shampoo
Number of subjects: 44
Study 21689115 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study 19112337 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryan Cervical Disc
Number of subjects: 463
Study 19112337 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion
Number of subjects: 463
Study 16461147 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut flour (doses ranging from 10 microg to 3 g)
Number of subjects: 27
Study 16461147 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut flour (doses ranging from 10 mg to 3 g)
Number of subjects: 27
Study 16461147 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary management over a 12-month period
Number of subjects: 27
Study 15238773 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ALCAR (1500 mg twice daily) for up to 33 months
Number of subjects: 21
Study 11753499 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional education program (9 sessions of one hour each over one year)
Number of subjects: 151
Study 11753499 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutritional sessions, normal follow-up advice)
Number of subjects: 151
Study 11753499 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional education program
Number of subjects: 151
Study 11753499 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 151
Study 9300221 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human insulin-like growth factor-1 (rhIGF-I)
Number of subjects: 0
Study 8363210 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapersonal standard deviation of weight (ISD) quartiles
Number of subjects: 10529
Study 3534801 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg hydrochlorothiazide
Number of subjects: 9
Study 3534801 — intervention group
Group type: EXPERIMENTAL
Intervention: 112.5 mg hydrochlorothiazide
Number of subjects: 9
Study 30890817 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing sessions (4 sessions, 15-20 minutes each)
Number of subjects: 60
Study 29957362 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling intervention leg cuff
Number of subjects: 276
Study 29957362 — intervention group
Group type: COMPARATOR
Intervention: Placebo cuff (control)
Number of subjects: 276
Study 26880373 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent program of discomfort reduction implemented over 6 months, including identification of discomforts, immediate feedback to the healthcare team, and implementation of targeted interventions.
Number of subjects: 660
Study 26880373 — intervention group
Group type: COMPARATOR
Intervention: Control group with no specific program implemented over 6 months.
Number of subjects: 660
Study 25203376 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable staple line reinforcement
Number of subjects: 302
Study 25203376 — intervention group
Group type: COMPARATOR
Intervention: Stapled circular anastomosis without reinforcement
Number of subjects: 302
Study 22709745 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pumping (IABP) in addition to early revascularization (either percutaneous coronary intervention or coronary artery bypass grafting)
Number of subjects: 600
Study 22709745 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy on the background of early revascularization (either percutaneous coronary intervention or coronary artery bypass grafting)
Number of subjects: 600
Study 22709745 — intervention group
Group type: EXPERIMENTAL
Intervention: IABP
Number of subjects: 600
Study 22709745 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 600
Study 21164555 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap water (W)
Number of subjects: 8
Study 21164555 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavored water (FW)
Number of subjects: 8
Study 21164555 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavored water with 6% carbohydrate and 18 mmol·L‐1 NaCl (CNa)
Number of subjects: 8
Study 17623067 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot compresses on the right upper abdomen
Number of subjects: 13
Study 17623067 — intervention group
Group type: COMPARATOR
Intervention: No hot compresses
Number of subjects: 13
Study 15590226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral program (CBP)
Number of subjects: 16
Study 12799509 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent pneumococcal conjugate vaccine (PnCRM9)
Number of subjects: 262
Study 12799509 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (meningococcus C vaccine)
Number of subjects: 262
Study 10423078 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer classes of blood pressure lowering drugs
Number of subjects: 270000
Study 10423078 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure lowering treatments
Number of subjects: 270000
Study 8558725 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised treadmill training (3 hr/wk at a work intensity sufficient to produce claudication)
Number of subjects: 29
Study 8558725 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised treadmill training continued for an additional 12 weeks
Number of subjects: 29
Study 8558725 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (3 hr/wk of resistive training of six muscle groups of each leg)
Number of subjects: 29
Study 8558725 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 29
Study 8558725 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve weeks of treadmill training after the strength training program
Number of subjects: 29
Study 8558725 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve weeks of combined treadmill and strength training after the control period
Number of subjects: 29
Study 1873659 — intervention group
Group type: EXPERIMENTAL
Intervention: Iotrolan (300 mgI/%),
Number of subjects: 0
Study 1873659 — intervention group
Group type: COMPARATOR
Intervention: Urografin (370 mgI/%),
Number of subjects: 0
Study 6223946 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy (BT)
Number of subjects: 25
Study 6223946 — intervention group
Group type: COMPARATOR
Intervention: Physical Therapy (PT)
Number of subjects: 25
Study 2580164 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 24
Study 2580164 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 24
Study 2580164 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril and Enalapril (combined therapy)
Number of subjects: 24
Study 2580164 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril and Enalapril (after prolonged treatment)
Number of subjects: 24
Study 30827252 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN) procedure
Number of subjects: 0
Study 30827252 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 0
Study 30017552 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (75–100 mg)
Number of subjects: 117279
Study 30017552 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of aspirin (≥325 mg)
Number of subjects: 117279
Study 30017552 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 117279
Study 26713666 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral pararectal stoma placement
Number of subjects: 60
Study 26713666 — intervention group
Group type: COMPARATOR
Intervention: Transrectal stoma placement
Number of subjects: 60
Study 24201303 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional programming with therapy for ventricular tachycardia ≥170 bpm
Number of subjects: 1500
Study 24201303 — intervention group
Group type: EXPERIMENTAL
Intervention: High-rate cutoff with therapy for ventricular tachycardia ≥200 bpm and a monitoring zone at 170 to 199 bpm
Number of subjects: 1500
Study 24201303 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged 60-second delay with a monitoring zone before therapy
Number of subjects: 1500
Study 24201303 — intervention group
Group type: EXPERIMENTAL
Intervention: Syncope (all types)
Number of subjects: 1500
Study 24201303 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical risk factors for syncope
Number of subjects: 1500
Study 23128163 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG145 280 mg
Number of subjects: 160
Study 23128163 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG145 350 mg
Number of subjects: 160
Study 23128163 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG145 420 mg
Number of subjects: 160
Study 23128163 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG145 420 mg + Ezetimibe 10 mg
Number of subjects: 160
Study 23128163 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Ezetimibe 10 mg
Number of subjects: 160
Study 21410069 — intervention group
Group type: EXPERIMENTAL
Intervention: Menatetrenone (4 5mg daily, orally)
Number of subjects: 40
Study 21410069 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study 17961145 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 169
Study 17961145 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 169
Study 17961145 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17‐beta estradiol
Number of subjects: 169
Study 17961145 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and vaginal 17‐beta estradiol
Number of subjects: 169
Study 17961145 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 169
Study 16632842 — intervention group
Group type: COMPARATOR
Intervention: Continuous spinal anesthesia (CSA) with titration of 2.5 mg boluses every 15 min of isobaric bupivacaine
Number of subjects: 74
Study 16632842 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection spinal anesthesia (SA) with 7.5 mg of isobaric bupivacaine
Number of subjects: 74
Study 11267624 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral hydrocortisone
Number of subjects: 0
Study 11267624 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral hydrocortisone
Number of subjects: 0
Study 11267624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9884705 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (40 Gy)
Number of subjects: 81
Study 9884705 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (surgery + radiotherapy)
Number of subjects: 81
Study 7857512 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum extracts (dosage: 300 to 900 mg total extract daily; duration: 2 to 6 weeks)
Number of subjects: 1592
Study 7857512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1592
Study 2543207 — intervention group
Group type: EXPERIMENTAL
Intervention: CAVE chemotherapy + RA233
Number of subjects: 101
Study 2543207 — intervention group
Group type: COMPARATOR
Intervention: CAVE chemotherapy
Number of subjects: 101
Study 132780 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximetasone (0.25%)
Number of subjects: 37
Study 132780 — intervention group
Group type: COMPARATOR
Intervention: Fluocinolone acetonide (0.2%)
Number of subjects: 37
Study 29877128 — intervention group
Group type: EXPERIMENTAL
Intervention: n-back training
Number of subjects: 41
Study 29877128 — intervention group
Group type: COMPARATOR
Intervention: Active control group (general knowledge and vocabulary task)
Number of subjects: 41
Study 29426608 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) at a dose of 10 mg/kg intravenously, 10 min preoperatively and 5 h postoperatively
Number of subjects: 100
Study 29426608 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 100
Study 26224543 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg once daily, n=125)
Number of subjects: 253
Study 26224543 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=128)
Number of subjects: 253
Study 23519040 — intervention group
Group type: EXPERIMENTAL
Intervention: Western healthcare class (36% of participants)
Number of subjects: 327
Study 23519040 — intervention group
Group type: EXPERIMENTAL
Intervention: Eastern healthcare class (18% of participants)
Number of subjects: 327
Study 23519040 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed healthcare class (46% of participants)
Number of subjects: 327
Study 22658688 — intervention group
Group type: EXPERIMENTAL
Intervention: Physio group (closed venous reservoir, phosphorylcholine coating, and no cardiotomy suction)
Number of subjects: 83
Study 22658688 — intervention group
Group type: COMPARATOR
Intervention: Standard group (open, noncoated, and cardiotomy suction used)
Number of subjects: 83
Study 19907419 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0
Study 19907419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18549992 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy deficit of at least 500 kcal per day
Number of subjects: 54
Study 18549992 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring adherence
Number of subjects: 54
Study 15987049 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker use for therapeutic prevention of atrial fibrillation
Number of subjects: 16
Study 15987049 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdrive pacing and different preventive pacing algorithms
Number of subjects: 16
Study 15987049 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual site pacing or septal pacing
Number of subjects: 16
Study 12732880 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF alone (10 mcg/kg/day)
Number of subjects: 52
Study 12732880 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide plus G‐CSF (Cyclophosphamide at 4 g/m(2) and G‐CSF at 10 mcg/kg/day)
Number of subjects: 52
Study 10199772 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2 plus TRH infusion (1 + 1 microg/kg x h) for 5 days
Number of subjects: 14
Study 10199772 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion for 5 days
Number of subjects: 14
Study 7767416 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain abdominal roentgenogram
Number of subjects: 60
Study 7767416 — intervention group
Group type: COMPARATOR
Intervention: Rectal examination
Number of subjects: 60
Study 2095530 — intervention group
Group type: EXPERIMENTAL
Intervention: Load 1 - 75% sound leg mass
Number of subjects: 6
Study 2095530 — intervention group
Group type: EXPERIMENTAL
Intervention: Load 2 - 100% sound leg mass
Number of subjects: 6
Study 2095530 — intervention group
Group type: COMPARATOR
Intervention: Load 0 - unloaded (39.1% sound shank mass)
Number of subjects: 6
Study 348293 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cyclophosphamide, adriamycin, and 5‐fluorouracil (CAF)
Number of subjects: 78
Study 348293 — intervention group
Group type: COMPARATOR
Intervention: Combination of cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF)
Number of subjects: 78
Study 348293 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF
Number of subjects: 78
Study 348293 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 78
Study 348293 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF and CMF
Number of subjects: 78
Study 31286426 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene education programme with digital tools (interactive android-based tablets)
Number of subjects: 377
Study 31286426 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 377
Study 30040076 — intervention group
Group type: EXPERIMENTAL
Intervention: Efgartigimod (FcRn antagonist)
Number of subjects: 62
Study 25982568 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined setting of one night wake therapy followed by 2 weeks bright light therapy
Number of subjects: 62
Study 25982568 — intervention group
Group type: COMPARATOR
Intervention: Bright light therapy alone
Number of subjects: 62
Study 24176585 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway scope (AWS)
Number of subjects: 109
Study 24176585 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope (MLS)
Number of subjects: 109
Study 22231691 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaoyang‐specific acupuncture
Number of subjects: 480
Study 22231691 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaoyang‐nonspecific acupuncture
Number of subjects: 480
Study 22231691 — intervention group
Group type: EXPERIMENTAL
Intervention: Yangming‐specific acupuncture
Number of subjects: 480
Study 22231691 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (control)
Number of subjects: 480
Study 21220791 — intervention group
Group type: EXPERIMENTAL
Intervention: Amineptine
Number of subjects: 15
Study 21220791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 16919506 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy with sustained-release tolterodine alone
Number of subjects: 307
Study 16919506 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy with sustained-release tolterodine combined with behavioral training (pelvic floor muscle exercise training, bladder control techniques, fluid management)
Number of subjects: 307
Study 16919506 — intervention group
Group type: COMPARATOR
Intervention: Control group (drug withdrawal and behavioral training stopped)
Number of subjects: 307
Study 16563280 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-adjusted dose rt-PA (42-92 mg, 1 mg/kg body weight)
Number of subjects: 184
Study 16563280 — intervention group
Group type: COMPARATOR
Intervention: Low dose rt-PA (42 mg over 90 minutes)
Number of subjects: 184
Study 16563280 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-adjusted dose rt-PA
Number of subjects: 184
Study 16563280 — intervention group
Group type: COMPARATOR
Intervention: Low dose rt-PA
Number of subjects: 184
Study 12189776 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gums (Superpep forte, 20 mg dimenhydrinate each, chewed for 30 min)
Number of subjects: 24
Study 12189776 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dimenhydrinate tablet
Number of subjects: 24
Study 12189776 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gums (Superpep forte)
Number of subjects: 24
Study 10596517 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐hr video‐based small group motivational‐skills intervention
Number of subjects: 117
Study 10596517 — intervention group
Group type: COMPARATOR
Intervention: 6‐hr video‐based contact‐matched HIV education comparison group
Number of subjects: 117
Study 7851574 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA) depot, 1.88 mg
Number of subjects: 36
Study 7851574 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA) depot, 3.75 mg
Number of subjects: 36
Study 1723456 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg
Number of subjects: 27
Study 1723456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 6935550 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil (1600 mg daily)
Number of subjects: 33
Study 6935550 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study 31480373 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk samples from mothers without celiac disease
Number of subjects: 569
Study 31480373 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk samples from mothers with celiac disease
Number of subjects: 569
Study 31480373 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk samples from different countries
Number of subjects: 569
Study 31480373 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk samples analyzed for IGF‐II and adiponectin
Number of subjects: 569
Study 28622941 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor loading dose (LD)
Number of subjects: 1862
Study 27381202 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based pulmonary rehabilitation
Number of subjects: 20
Study 27381202 — intervention group
Group type: COMPARATOR
Intervention: Conventional pulmonary rehabilitation
Number of subjects: 20
Study 25407420 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing with soap
Number of subjects: 0
Study 25407420 — intervention group
Group type: COMPARATOR
Intervention: No handwashing
Number of subjects: 0
Study 25407420 — intervention group
Group type: EXPERIMENTAL
Intervention: Child care activities
Number of subjects: 0
Study 25407420 — intervention group
Group type: EXPERIMENTAL
Intervention: Agricultural activities
Number of subjects: 0
Study 25407420 — intervention group
Group type: EXPERIMENTAL
Intervention: Food preparation activities
Number of subjects: 0
Study 25407420 — intervention group
Group type: COMPARATOR
Intervention: Water access, latrine type, education, or diarrhoea
Number of subjects: 0
Study 22431131 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/day orally
Number of subjects: 50
Study 22431131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19837431 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 mA seconds
Number of subjects: 14
Study 19837431 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mA seconds
Number of subjects: 14
Study 19837431 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mA seconds
Number of subjects: 14
Study 19837431 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mA seconds
Number of subjects: 14
Study 19837431 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mA seconds
Number of subjects: 14
Study 19837431 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mA seconds
Number of subjects: 14